This story has been updated with details about an additional trial in the neoadjuvant setting.
NEW YORK – MacroGenics published results in JAMA Oncology on Friday from the Phase III SOPHIA trial demonstrating the ability of its monoclonal antibody margetuximab (Margenza) plus chemotherapy to extend progression-free survival in metastatic, HER2-positive breast cancer patients compared to trastuzumab (Genentech's Herceptin) plus chemo.